Credit Agricole S A Arcus Biosciences, Inc. Transaction History

Credit Agricole S A

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$26.93 - $37.68 $166,966 - $233,616	-6,200 Closed	0 $0
Q2 2021 Aug 10, 2021	BUY	$22.75 - $35.77 $45,500 - $71,540	2,000 Added 47.62%	6,200 $170,000
Q1 2021 May 17, 2021	BUY	$26.16 - $41.39 $109,872 - $173,838	4,200 New	4,200 $118,000

201

51.7M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.06B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Credit Agricole S A, based on Form 13F filings with the SEC.

Stay updated on Credit Agricole S A with notifications on news.